Patents by Inventor Pingda Ren

Pingda Ren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of ERK and methods of use
    Patent number: 9624228
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as ERK (MAPK). Also provided are methods of using such compounds or compositions, and methods of using these compositions to modulate the activities of one or more of these kinases, especially for therapeutic applications such as the treatment disorders such as cancer.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: April 18, 2017
    Assignee: Kura Oncology, Inc.
    Inventors: Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
  • Heterocyclic compounds and uses thereof
    Patent number: 9605003
    Abstract: Substituted bicyclic heterocyclic compounds such as isoquinolinone compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: March 28, 2017
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Catherine A. Evans, Andre Lescarbeau, Tao Liu, Daniel A. Snyder, Martin R. Tremblay, Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan
  • SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170022184
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R2a, R2b, R2c, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Application
    Filed: July 22, 2016
    Publication date: January 26, 2017
    Inventors: Liansheng Li, Jun Feng, Yun Oliver Long, Yuan Liu, Tao Wu, Pingda Ren, Yi Liu
  • Heterocyclic compounds and uses thereof
    Patent number: 9546180
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: January 17, 2017
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Daniel A. Snyder, Martin R. Tremblay, Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan
  • Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
    Patent number: 9522146
    Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: December 20, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
  • SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160297774
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, B, G1, G2, L1, L2, m1, m2, n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Application
    Filed: April 8, 2016
    Publication date: October 13, 2016
    Inventors: Liansheng Li, Jun Feng, Yun Oliver Long, Yuan Liu, Tao Wu, Pingda Ren, Yi Liu
  • Treatment Regimens Using Multiple Pharmaceutical Agents
    Publication number: 20160287597
    Abstract: The present invention provides for methods and pharmaceutical compositions for treating disorders using treatment regimens involving multiple agents. In one aspect, a method of treatment is provided resulting in reduced toxicity and/or synergistic effect by administration according to a described dosing schedule.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 6, 2016
    Inventors: Yi Liu, Shunyou Wang, Matthew R. Janes, Guibei Lan, Pingda Ren, Christian Rommel
  • Benzoxazole Kinase Inhibitors and Methods of Use
    Publication number: 20160287596
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.
    Type: Application
    Filed: April 7, 2016
    Publication date: October 6, 2016
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
  • Combination Pharmaceutical Compositions and Uses Thereof
    Publication number: 20160287595
    Abstract: The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.
    Type: Application
    Filed: April 7, 2016
    Publication date: October 6, 2016
    Inventors: Yi Liu, Pingda Ren, Katayoun Jessen, Xin Guo, Christian Rommel
  • INHIBITORS OF ERK AND METHODS OF USE
    Publication number: 20160237091
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as ERK (MAPK). Also provided are methods of using such compounds or compositions, and methods of using these compositions to modulate the activities of one or more of these kinases, especially for therapeutic applications such as the treatment disorders such as cancer.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 18, 2016
    Inventors: Liansheng LI, Tao Wu, Jun FENG, Pingda REN, Yi LIU
  • COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF
    Publication number: 20160235758
    Abstract: The present invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.
    Type: Application
    Filed: February 11, 2016
    Publication date: August 18, 2016
    Inventors: Pingda Ren, Yi Liu, Katayoun Jessen, Xin Guo, Christian Rommel, Troy Edward Wilson
  • Kinase inhibitor polymorphs
    Patent number: 9403820
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3K activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3K activity, are described herein.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: August 2, 2016
    Assignees: Intellikine LLC, Sigma-Aldrich Company Limited
    Inventors: Pingda Ren, Michael Martin, Christopher Peter Worrall, Susanna del Rio Gancedo
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20160207940
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: December 16, 2015
    Publication date: July 21, 2016
    Inventors: Alfredo C. CASTRO, Katrina CHAN, Catherine A. EVANS, Somarajannair JANARDANANNAIR, Andre LESCARBEAU, Liansheng LI, Tao LIU, Yi LIU, Pingda REN, Daniel A. SNYDER, Martin R. TREMBLAY
  • Heterocyclic compounds and uses thereof
    Patent number: 9388183
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: July 12, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Alfredo C. Castro, Catherine A. Evans, Daniel A. Snyder
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
    Publication number: 20160185800
    Abstract: Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.
    Type: Application
    Filed: March 3, 2016
    Publication date: June 30, 2016
    Inventors: Pingda REN, Yi LIU, Troy Edward WILSON, Katrina CHAN, Christian ROMMEL, Liansheng LI
  • HETEROCYCLIC KINASE INHIBITORS
    Publication number: 20160168157
    Abstract: The present invention provides heterocyclic compounds for use as kinase inhibitors and in other applications. Also provided are pharmaceutical compositions and methods of treatments of diseases and conditions associated with P13 kinase activity.
    Type: Application
    Filed: February 22, 2016
    Publication date: June 16, 2016
    Inventors: Pingda REN, Yi LIU, Liansheng LI, Katrina CHAN, Troy Edward WILSON
  • COMBINATION THERAPIES FOR TREATMENT OF CANCER
    Publication number: 20160166571
    Abstract: Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
    Type: Application
    Filed: September 18, 2015
    Publication date: June 16, 2016
    Inventors: Matthew Robert Janes, Matthew Peter Patricelli, Liansheng Li, Pingda Ren, Yi Liu
  • COVALENT INHIBITORS OF KRAS G12C
    Publication number: 20160159738
    Abstract: Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
    Type: Application
    Filed: November 5, 2015
    Publication date: June 9, 2016
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Jun Feng, Tao Wu
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
    Publication number: 20160158239
    Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
    Type: Application
    Filed: November 11, 2015
    Publication date: June 9, 2016
    Inventors: Pingda REN, Yi LIU, Troy Edward WILSON, Liansheng LI, Katrina CHAN, Christian ROMMEL
  • Substituted benzimidazoles as PI3 kinase inhibitors
    Patent number: 9359352
    Abstract: The present invention provides substituted benzimidazole compounds of Formula I: wherein the variables R1, R2, W1, W2, W3, W4, W5, W6, Wa, Wb, Wc and Wd are defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 7, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell